Markets · 1 sources covering this

J&J Has No Plans to Enter Obesity Drugs Market, CEO Says

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk. (Source: Bloomberg)

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·3h ago
J&J Has No Plans to Enter Obesity Drugs Market, CEO Says
Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk. (Source: Bloomberg)
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/15022593342a67263e3dbd2a2f0947f388812922"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="J&J Has No Plans to Enter Obesity Drugs Market, CEO Says"></iframe>

J&J Has No Plans to Enter Obesity Drugs Market, CEO Says

How 1 sources are covering this